Littérature scientifique sur le sujet « Cardiac amyloidosi »

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Cardiac amyloidosi ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Cardiac amyloidosi"

1

Guan, Jian, Shikha Mishra, Rodney H. Falk, and Ronglih Liao. "Current perspectives on cardiac amyloidosis." American Journal of Physiology-Heart and Circulatory Physiology 302, no. 3 (2012): H544—H552. http://dx.doi.org/10.1152/ajpheart.00815.2011.

Texte intégral
Résumé :
Amyloidosis represents a group of diseases in which proteins undergo misfolding to form insoluble fibrils with subsequent tissue deposition. While almost all deposited amyloid fibers share a common nonbranched morphology, the affected end organs, clinical presentation, treatment strategies, and prognosis vary greatly among this group of diseases and are largely dependent on the specific amyloid precursor protein. To date, at least 27 precursor proteins have been identified to result in either local tissue or systemic amyloidosis, with nine of them manifesting in cardiac deposition and resultin
Styles APA, Harvard, Vancouver, ISO, etc.
2

Zattar Piazera, Flávia, Lucas Dornas Xavier, Natalye Wynona Rosário Cunha, Taís Nunes dos Santos, and Alex Francisco Antônio de Souza Damaceno. "The challenge of clinical diagnosis of cardiac amyloidosis: Case report and literature review." International Journal of Case Reports and Images 15, no. 2 (2024): 10–14. http://dx.doi.org/10.5348/101461z01fp2024cr.

Texte intégral
Résumé :
Introduction: Cardiac amyloidosis is a disease caused by the deposition and extracellular accumulation of defective proteins (amyloids) in the myocardium, which can lead to conduction disorders, diastolic dysfunction, and restriction to ventricular filling resulting in reduction of systolic volume and of cardiac output. Case Report: The patient, a 62-year-old male with a history of ischemic stroke for two months, was referred to the outpatient clinic for investigation of thrombophilia due to echocardiographic changes suggestive of cardiac amyloidosis. Conclusion: Cardiac amyloidosis is an unde
Styles APA, Harvard, Vancouver, ISO, etc.
3

Niemiec, Małgorzata, Magdalena Balwierz, Bartosz Gruchlik, and Katarzyna Mizia-Stec. "Cardiac amyloidosis." Annales Academiae Medicae Silesiensis 78 (June 25, 2024): 146–54. http://dx.doi.org/10.18794/aams/183982.

Texte intégral
Résumé :
Amyloidoza jest rzadką chorobą charakteryzującą się nieprawidłowym gromadzeniem się białka amyloidowego w tkankach. Amyloidozę można podzielić na dwa główne podtypy: amyloidozę transtyretynową (ATTR-CA) i amyloidozę łańcuchów lekkich immunoglobulin (AL-CA). Nagromadzenie białka amyloidu w mięśniu sercowym może doprowadzić do zaburzeń przewodzenia, kardiomiopatii restrykcyjnej i w konsekwencji niewydolności serca. Objawy mogą obejmować spadek tolerancji wysiłku, duszność, obrzęki oraz omdlenia. Rozpoznanie opiera się na badaniach laboratoryjnych, obrazowych oraz biopsji. Leczenie koncentruje si
Styles APA, Harvard, Vancouver, ISO, etc.
4

Musetti, Veronica, Francesco Greco, Vincenzo Castiglione, et al. "Tissue Characterization in Cardiac Amyloidosis." Biomedicines 10, no. 12 (2022): 3054. http://dx.doi.org/10.3390/biomedicines10123054.

Texte intégral
Résumé :
Cardiac amyloidosis (CA) has long been considered a rare disease, but recent advancements in diagnostic tools have led to a reconsideration of the epidemiology of CA. Amyloid light-chain (AL) and transthyretin (ATTR) amyloidoses are the most common forms of cardiac amyloidosis. Due to the distinct treatments and the different prognoses, amyloid typing is crucial. Although a non-biopsy diagnosis can be obtained in ATTR amyloidosis when certain diagnostic criteria are fulfilled, tissue characterization still represents the gold standard for the diagnosis and typing of CA, particularly in AL amyl
Styles APA, Harvard, Vancouver, ISO, etc.
5

Ablasser, Klemens, Nicolas Verheyen, Theresa Glantschnig, Giulio Agnetti, and Peter P. Rainer. "Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure." Current Medicinal Chemistry 26, no. 16 (2019): 2865–78. http://dx.doi.org/10.2174/0929867325666180104153338.

Texte intégral
Résumé :
Deposition of amyloidogenic proteins leading to the formation of amyloid fibrils in the myocardium causes cardiac amyloidosis. Although any form of systemic amyloidosis can affect the heart, light-chain (AL) or transthyretin amyloidosis (ATTR) account for the majority of diagnosed cardiac amyloid deposition. The extent of cardiac disease independently predicts mortality. Thus, the reversal of arrest of adverse cardiac remodeling is the target of current therapies. Here, we provide a condensed overview on the pathophysiology of AL and ATTR cardiac amyloidoses and describe treatments that are cu
Styles APA, Harvard, Vancouver, ISO, etc.
6

de Barros Correia, Edileide, Larissa Ventura Ribeiro Bruscky, Georgina del Cisne Jadán Luzuriaga, Bruno Vaz Kerges Bueno, and Marcus Vinicius Simões. "AMILOIDOSE CARDÍACA: O QUE HÁ DE NOVO." Revista da Sociedade de Cardiologia do Estado de São Paulo 33, no. 3 (2023): 294–303. http://dx.doi.org/10.29381/0103-8559/20233303294-303.

Texte intégral
Résumé :
Amiloidose se refere a um conjunto de doenças causadas pelo depósito de fragmentos anômalos de diferentes proteínas. O coração é um dos principais órgãos afetados, nas formas mais comuns de amiloidose, com os pacientes apresentando mau prognóstico e sobrevida curta, conforme o grau de acometimento. Embora considerada uma afecção rara, vários trabalhos têm demonstrado um aumento expressivo no número de diagnósticos nos últimos anos. Tem contribuído para isso o maior arsenal diagnóstico não invasivo, com novas ferramentas de avaliação mais específicas em exames já consagrados na prática clínica
Styles APA, Harvard, Vancouver, ISO, etc.
7

Yilmaz, A., J. Bauersachs, F. Bengel, et al. "Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)." Clinical Research in Cardiology 110, no. 4 (2021): 479–506. http://dx.doi.org/10.1007/s00392-020-01799-3.

Texte intégral
Résumé :
AbstractSystemic forms of amyloidosis affecting the heart are mostly light-chain (AL) and transthyretin (ATTR) amyloidoses. The latter is caused by deposition of misfolded transthyretin, either in wild-type (ATTRwt) or mutant (ATTRv) conformation. For diagnostics, specific serum biomarkers and modern non-invasive imaging techniques, such as cardiovascular magnetic resonance imaging (CMR) and scintigraphic methods, are available today. These imaging techniques do not only complement conventional echocardiography, but also allow for accurate assessment of the extent of cardiac involvement, in ad
Styles APA, Harvard, Vancouver, ISO, etc.
8

Wisniowski, Brendan, and Ashutosh Wechalekar. "Confirming the Diagnosis of Amyloidosis." Acta Haematologica 143, no. 4 (2020): 312–21. http://dx.doi.org/10.1159/000508022.

Texte intégral
Résumé :
Amyloidosis is a general term for diseases characterised by the deposition of insoluble amyloid fibrils in organs or tissues, leading to organ dysfunction and, in many cases, death. Amyloid fibrils are derived from soluble precursor proteins, with the number of known amyloidogenic proteins increasing over time. The identity of the precursor protein often predicts the disease phenotype, although many of the amyloidoses have overlapping clinical features. Most patients with amyloidosis will require biopsy of an involved organ or tissue to confirm the diagnosis. Cardiac transthyretin amyloidosis,
Styles APA, Harvard, Vancouver, ISO, etc.
9

Herzog, Eyal, David Leibowitz, Moshe E. Gatt, Tali Koren, and Arthur Pollak. "Pathway for the Diagnosis and Management of Cardiac Amyloidosis." Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 22, no. 4 (2023): 114–19. http://dx.doi.org/10.1097/hpc.0000000000000331.

Texte intégral
Résumé :
The systemic amyloidoses are a broad spectrum of diseases that result from misfolding of proteins that aggregate into amyloid fibrils. In cardiac amyloidosis, amyloid fibrils accumulate in the interstitial space between cardiac myocytes causing cellular injury and impairing compliance. Current data suggest that cardiac amyloidosis is more common than previously thought. Advances in cardiac imaging, diagnostic strategies, and therapies have improved the recognition and treatment of cardiac amyloidosis. A position statement for the diagnosis and treatment of cardiac amyloidosis has been publishe
Styles APA, Harvard, Vancouver, ISO, etc.
10

Ruiz-Mori, Enrique, Leonor Ayala-Bustamante, Luis Taxa-Rojas, Cristian Pacheco-Román, Javier Alarcón-Santos, and Jorge Burgos-Bustamante. "Amiloidosis cardiaca: reporte de un caso." Horizonte Médico (Lima) 18, no. 4 (2018): 81–89. http://dx.doi.org/10.24265/horizmed.2018.v18n4.12.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "Cardiac amyloidosi"

1

RELLA, VALERIA. "AMILOIDOSI CARDIACA ANALISI DI PREVALENZA IN DUE STUDI MULTICENTRICI ITALIANI." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2022. http://hdl.handle.net/10281/366496.

Texte intégral
Résumé :
Tra i pazienti con diagnosi iniziale di cardiomiopatia ipertrofica afferiti a Centri di Riferimento per le Cardiomiopatie, l’AC è la malattia non riconosciuta più comune con una prevalenza complessiva del 9%, e che aumenta con l'età (dall'1% nella fascia di età tra i 40-49 anni al 26% sopra gli 80 anni). Nella popolazione generale ≥55 anni più del 7% ha almeno un reperto ecocardiografico suggestivo di AC e l’ispessimento del setto interatriale è quello più frequente. I pazienti con elevato sospetto di AC (≥3 reperti) rappresentano l’1% della popolazione generale e il 4,9% di quelli con cuore n
Styles APA, Harvard, Vancouver, ISO, etc.
2

Lachira-Yparraguirre, Lizbeth, Ali Al-kassab-Córdova, Edgar Quispe-Silvestre, and Daniel Enriquez-Vera. "Cardiac amyloidosis secondary to waldenström macroglobulinemia." Editorial Ciencias Medicas, 2020. http://hdl.handle.net/10757/655705.

Texte intégral
Résumé :
Introduction: Waldenström's macroglobulinemia is a hematological neoplasm belonging to the group of monoclonal gammopathies, which includes systemic symptoms and those related to an increase in M paraprotein. Objective: To describe a case of cardiac amyloidosis associated with macroglobulinemia. Clinical case: Male patient who was admitted for asthenia, dysphonia, and who, during his evolution, developed progressive dyspnea, heart failure and pleural effusion. Additionally, echocardiography showed myocardial granular pattern, while pleural biopsy was positive for Congo red staining. Subsequent
Styles APA, Harvard, Vancouver, ISO, etc.
3

Arvidsson, Sandra. "Cardiac function in hereditary transthyretin amyloidosis : an echocardiographic study." Doctoral thesis, Umeå universitet, Institutionen för folkhälsa och klinisk medicin, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-113891.

Texte intégral
Résumé :
Background: Hereditary transthyretin amyloidosis (ATTR) is a lethal disease in which misfolded transthyretin (TTR) proteins accumulate as insoluble aggregates in tissues throughout the body. A common mutation is the exchange of valine to methionine at place 30 (TTR V30M), a form endemically found in the northern parts of Sweden. The main treatment option for ATTR amyloidosis is liver transplantation as the procedure halts production of mutated transthyretin. The disease is associated with marked phenotypic diversity ranging from predominant cardiac complications to pure neuropathy. Two differe
Styles APA, Harvard, Vancouver, ISO, etc.
4

Dungu, Jason N. "Cardiac transthyretin amyloidosis in the British African and Caribbean population." Thesis, St George's, University of London, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.676103.

Texte intégral
Résumé :
Cardiac amyloidosis is a condition characterised by infiltration of the myocardium with fibrillar proteins. Transthyretin (TTR) is a plasma protein that may form amyloid fibrils and the V122I mutant form of TTR is associated with isolated cardiac amyloidosis. Previous studies have estimated a 4% V122I allele frequency in African Americans. The prevalence of cardiac transthyretin amyloidosis (ATTR) V122I in the British population is not known. I was awarded a British Heart Foundation Clinical Research Fellowship to investigate the diagnosis and prevalence of ATTR V122I in the UK population. Mor
Styles APA, Harvard, Vancouver, ISO, etc.
5

Rausch, Karen. "Application of left atrial strain assessment by 2D echocardiography in cardiac conditions involving the left atrium including cardiac amyloidosis." Thesis, Griffith University, 2020. http://hdl.handle.net/10072/400573.

Texte intégral
Résumé :
The left atrium (LA) plays an important role in the modulation of LV filling and contributes to LV stroke volume with atrial contraction. Despite this important role, much research to date has been focused on the ventricles in disease, rather than the atria. In recent years there has been increasing interest and excitement in the function of the LA in normal and disease states – no longer is the LA secondary to the left ventricle (LV). The LA has three major functions: reservoir, conduit and contractile. The LA acts as a reservoir during ventricular systole as it fills with blood via the pulmo
Styles APA, Harvard, Vancouver, ISO, etc.
6

Pilebro, Björn. "The heart in hereditary transthyretin amyloidosis : clinical studies on the impact of amyloid fibril composition." Doctoral thesis, Umeå universitet, Medicin, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-139495.

Texte intégral
Résumé :
Background Hereditary transthyretin amyloid (ATTRm) amyloidosis is a systemic disease mainly affecting the peripheral nervous system and the heart. The disease is inherited in an autosomal dominant manner with a varying penetrance. It is caused by mutations in the transthyretin (TTR) gene. Today more than 100 disease causing mutations are known. The V30M mutation that is endemic in northern Sweden is the best studied and comprises the majority of the reported disease cases in the world. In ATTRm amyloidosis caused by the V30M mutation two distinct sub populations are seen, one with disease ons
Styles APA, Harvard, Vancouver, ISO, etc.
7

Hörnsten, Rolf. "Cardiac arrhythmias and heart rate variability in familial amyloidotic polyneuropathy : a clinical study before and after liver transplantation /." Umeå : Univ, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1407.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Hörnsten, Rolf. "Cardiac arrhythmias and heart rate variability in familial amyloidotic polyneuropathy : A clinical study before and after liver transplantation." Doctoral thesis, Umeå universitet, Kirurgisk och perioperativ vetenskap, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1407.

Texte intégral
Résumé :
Familial amyloidotic polyneuropathy (FAP), found in the northernmost counties in Sweden, is a rare, lethal and inherited amyloidosis. The disease is caused by mutated transthyretin (TTR). The mutation is characterized by an exchange of valine for methionine at position 30 (ATTRVal30Met). FAP is characterised by progressive polyneuropathy affecting both the peripheral and autonomic nervous system (ANS). Cardiac arrhythmia and autonomic disturbances are common as well as gastrointestinal symptoms: such as constipation and diarrhoea. Today, orthotopic liver transplantation (LTx) is the only treat
Styles APA, Harvard, Vancouver, ISO, etc.
9

Damerjian, Vera. "La caractérisation du speckle sur des images échocardiographiques afin de définir des indices diagnostiques de l'amylose cardiaque et personnaliser un modèle numérique du coeur." Thesis, Paris Est, 2016. http://www.theses.fr/2016PESC1035.

Texte intégral
Résumé :
L’Hypertrophie Ventriculaire Gauche (HVG) est actuellement mise en évidence par échographie. Cet examen fournit des informations anatomo-fonctionnelles mais ne permet pas de déterminer l’étiologie des HVG, ce qui engendre de graves erreurs de diagnostic et de prise en charge thérapeutique. Les HVG sont classiquement séparées en 2 catégories :1. pathologies hypertrophiques induites par la modification structurelle et fonctionnelle des cardiomyocites qui tend à compenser des insuffisances cardiaques liées par exemple à des problèmes d’hypertension artérielle, de rétrécissement aortique ou de Car
Styles APA, Harvard, Vancouver, ISO, etc.
10

Nokwe, Nkumbe Cardine [Verfasser], Johannes [Akademischer Betreuer] [Gutachter] Buchner, and Bernd [Gutachter] Reif. "Molecular determinants and mechanisms of antibody light chain (AL) amyloidosis / Cardine Nokwe Nkumbe ; Gutachter: Bernd Reif, Johannes Buchner ; Betreuer: Johannes Buchner." München : Universitätsbibliothek der TU München, 2014. http://d-nb.info/1122738293/34.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Livres sur le sujet "Cardiac amyloidosi"

1

Emdin, Michele, Giuseppe Vergaro, Alberto Aimo, and Marianna Fontana, eds. Cardiac Amyloidosis. Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-51757-0.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Herzog, Eyal, ed. Cardiac Amyloidosis. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-88342-2.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Zacek, Pavel. Amyloidosis and Cardiac Surgery. INTECH Open Access Publisher, 2012.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Vergaro, Giuseppe, Alberto Aimo, and Marianna Fontana. Cardiac Amyloidosis: Diagnosis and Treatment. Springer, 2024.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Sabharwal, Nikant, Parthiban Arumugam, and Andrew Kelion. Other nuclear cardiological investigations. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198759942.003.0011.

Texte intégral
Résumé :
This chapter explains the imaging protocol physiological properties and clinical value of other nuclear cardiological investigations. It covers iodine-123-labelled radiopharmaceuticals, iodine-123-meta-iodo-benzyl-guanidine (123I-MIBG), β‎-methyl-p-[123I]iodo-phenyl-pentadecanoic acid (123I-BMIPP), and Tc-phosphate scintigraphy for cardiac amyloidosis, exploring both practical and clinical aspects. Specific prognoses and diagnoses are also detailed for the relevant investigation, including systolic heart failure, coronary artery disease, and cardiac amyloidosis.
Styles APA, Harvard, Vancouver, ISO, etc.
6

Lombardi, Massimo, and Antonia Camporeale. Cardiovascular magnetic resonance in less common pathologies. Edited by Dudley Pennell. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0111.

Texte intégral
Résumé :
Contrast-enhanced cardiovascular magnetic resonance plays a pivotal role in diagnostic and prognostic definition of less common pathologies such as Anderson–Fabry disease, cardiac amyloidosis, left ventricular non-compaction, sarcoidosis, and cardiac iron loading.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Płońska-Gościniak, Edyta, Michal Ciurzynski, Marcin Fijalkowski, et al. Cardiac involvement in systemic diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198726012.003.0057.

Texte intégral
Résumé :
Cardiovascular features in systemic diseases are common. Transthoracic echocardiography represents a first-line diagnostic tool among these patients. Pericarditis is the most frequent cardiac complication of rheumatoid arthritis. In systemic lupus erythematosus, echocardiography shows usually small or moderate pericardial effusion in up to 55% of patients. In this group, Libman-Sacks vegetations develop mainly on the mitral valve but also can be seen on other valves. Pulmonary hypertension is one of the most important complications adversely influencing survival of systemic sclerosis patients.
Styles APA, Harvard, Vancouver, ISO, etc.
8

Klarich, Kyle W. The Heart and Systemic Disease, Pregnancy and Heart Disease, and Miscellaneous Cardiac Disorders. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199755691.003.0047.

Texte intégral
Résumé :
Many systemic diseases may have manifestations in the heart. This section describes those that are most likely to be included on the examination: hyperthyroidism, hypothyroidism, diabetes mellitus, amyloidosis, hemochromatosis, carcinoid disease, systemic lupus erythematosus, hypereosinophilic syndrome, scleroderma, and rheumatoid arthritis, among others, are included. Sections on pericardial disease, tumors of the heart, and valve diseases are covered. Physiologic changes of the heart in pregnancy and their effect on existing heart disease are also reviewed.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Lancellotti, Patrizio, and Bernard Cosyns. Systemic Disease and Other Conditions. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198713623.003.0017.

Texte intégral
Résumé :
This chapter describes the effect of various activities on the heart and associated disorders. It details the echocardiographic findings of athlete’s heart and differential diagnosis. It considers pregnancy which induces several haemodynamic changes: increase in heart rate, stroke volume, cardiac output, and decrease in systemic vascular resistance. Several echocardiographic changes may also present in normal pregnancy and these must be recognized. Echocardiography should be performed in each pregnant woman with cardiac signs or symptoms to search for new cardiac disease occurring during pregn
Styles APA, Harvard, Vancouver, ISO, etc.
10

Dorbala, Sharmila, and Katarina H. Nelson. Inflammatory and Infiltrative Diseases and Tumors. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199392094.003.0026.

Texte intégral
Résumé :
This chapter highlights some of the novel clinical radionuclide imaging strategies beyond perfusion imaging including inflammatory diseases, infiltrative diseases and tumors. Targeted molecular imaging techniques to evaluate cardiac amyloidosis as well as myocardial and vascular inflammation are addressed. Clinical 18F-FDG imaging of cardiac sarcoidosis, cardiovascular prosthetic valve and device infections, systemic vasculitis, and tumors are discussed in detail. For each of these pathologies, a concise overview of the disease pathophysiology and management pertinent to understanding of imagi
Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Cardiac amyloidosi"

1

Tan, Carmela D., and E. Rene Rodriguez. "Cardiac Amyloidosis." In Current Clinical Pathology. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-19294-9_29.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Alpert, Martin A. "Cardiac Amyloidosis." In Cancer and the Heart. Springer New York, 1986. http://dx.doi.org/10.1007/978-1-4612-4898-9_14.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Barbarossa, Alessandro, and Erika Baiocco. "Cardiac Amyloidosis." In Clinical Cases in Cardiology. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-19926-9_12.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Tan, Carmela D., and E. Rene Rodriguez. "Cardiac Amyloidosis." In Amyloid and Related Disorders. Humana Press, 2012. http://dx.doi.org/10.1007/978-1-60761-389-3_26.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Wong, Liza S. M., and Daniel P. Judge. "Cardiac Amyloidosis." In Clinical Cardiogenetics. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-45457-9_10.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Sun, Jing Ping, Xing Sheng Yang, Bryan P. Yan, and Ka-Tak Wong. "Cardiac Amyloidosis." In Comparative Cardiac Imaging. John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119453192.ch49.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Porcari, Aldostefano, Gianfranco Sinagra, Marianna Fontana, and Silvia Pica. "Cardiac Amyloidosis." In Case-based Atlas of Cardiovascular Magnetic Resonance. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-32593-9_7.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Sun, Jing Ping, and Dan Sorescu. "Cardiac Amyloidosis." In Practical Handbook of Echocardiography. Wiley-Blackwell, 2010. http://dx.doi.org/10.1002/9781444320367.ch84.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Lee Chuy, Katherine, Saurabh Malhotra, and Jennifer E. Liu. "Cardiac Amyloidosis." In Atlas of Imaging in Cardio-Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-70998-3_18.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Haaf, Philip, Irene A. Burger, Michael J. Zellweger, Pankaj Garg, and Cristina E. Popescu. "Cardiac Amyloidosis." In Imaging of Inflammation and Infection in Cardiovascular Diseases. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-81131-0_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Cardiac amyloidosi"

1

Li, Xiaofeng, Hongmei Zhang, Xiaoxian Luo, Jiachen Dang, Lixue Yin, and Bo Peng. "Discrimination and Diagnosis of Hypertrophic Cardiomyopathy and Cardiac Amyloidosis via Unimodal Supervision Joint Contrastive Learning." In 2024 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2024. https://doi.org/10.1109/bibm62325.2024.10821844.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Law, Isaac, and Shankar Vamadevan. "Imaging Of ATTR Cardiac Amyloidosis." In Radiopaedia 2024 Virtual Conference. Radiopaedia.org, 2024. http://dx.doi.org/10.53347/rposter-2496.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Morozkina, Svetlana N., Petr P. Snetkov, and Mayya V. Uspenskaya. "Docking of Small Molecules with in Vivo Cardiovascular Activity into The Proteins – The Relationship with Side-Effects." In International Medicine and Health Sciences Congress. ECER, 2024. https://doi.org/10.53375/imhsc.2024.35.

Texte intégral
Résumé :
Cardiac amyloidosis is a clinical pathology, usually of a genetically mediated nature, initiated by the formation of amyloid fibrils, that lead to death. The number of clinically used molecules for the treatment of cardiac amyloidosis is very limited with strong side effects (for example, tafamidis and diflunisal). In this study, the methods of molecular modeling and computer docking of ligands using ICM-pro (Molsoft LLS, USA) were used to evaluate for the first time the level of side binding of small molecules possessing in vivo cardiovascular activity into the ligand-binding domains of 136 p
Styles APA, Harvard, Vancouver, ISO, etc.
4

Richardson, Michelle, Mahesh Prahladan, and Zafah Ullah. "32 Cardiac amyloidosis with dominant autonomic involvement." In British Cardiovascular Society Annual Conference, ‘Future-proofing Cardiology for the next 10 years’, 5–7 June 2023. BMJ Publishing Group Ltd and British Cardiovascular Society, 2023. http://dx.doi.org/10.1136/heartjnl-2023-bcs.32.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Toor, S., K. Rau, P. Kurecka, and D. Cameron. "A Curious Case of Presumed Cardiac Amyloidosis." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1737.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Uspenskaya, Mayya V., Petr P. Snetkov, Yuliya E. Generalova, and Svetlana N. Morozkina. "Drug Delivery Systems for Clinically used Drugs for Cardiac Amyloidosis Treatment: Preparation and Properties." In International Medicine and Health Sciences Congress. ECER, 2024. https://doi.org/10.53375/imhsc.2024.36.

Texte intégral
Résumé :
Cardiac amyloidosis is one of the leading causes of restrictive cardiomyopathy. It is typically rapidly progressive diastolic dysfunction in a non-dilated ventricle. Due to the numerous molecular pathways involved in the development andprogression of the disease, the drug molecules useful for cardiac amyloidosis are represented only by two small molecules, introduced in clinical application relatively recently. Here we present the comparative analysis of drug delivery systems for tafamidis and diflunisal, which have been developed in our group. The biosafe and biodegradable polymeric matrixes
Styles APA, Harvard, Vancouver, ISO, etc.
7

Connolly, M., A. Fallon, D. Waterhouse, and R. O’Hanlon. "45 Progression of cardiac amyloid fibril infiltration in cardiac amyloidosis using cardiac magnetic resonance." In Irish Cardiac Society Annual Scientific Meeting & AGM, Thursday October 4th – Saturday October 6th 2018, Galway Bay Hotel, Galway, Ireland. BMJ Publishing Group Ltd and British Cardiovascular Society, 2018. http://dx.doi.org/10.1136/heartjnl-2018-ics.45.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Tran, T., K. Tsarova, H. Desai, and W. G. Carlos. "An Atypical and Acute Presentation of Cardiac Amyloidosis." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3491.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Mohd Sabri, Nurul Miftah Binti, Nik Ahmad Hilmi bin Nik Mohd Zaid, Siti Aisyah Hussin, W. Yus Haniff W. Isa MD, Zurkurnai Yusof, and Abu Dzarr Abdullah. "APCU 06 Multiple myeloma coexistence with cardiac amyloidosis." In APCU@USM 2024 abstracts. British Cardiovascular Society, 2025. https://doi.org/10.1136/openhrt-2024-apcu.6.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Kotecha, Tushar, Esther Gonzalez-Lopez, Andrej Corovic, et al. "21 Intracardiac thrombi in cardiac amyloidosis, a common finding." In British Society of Cardiovascular Magnetic Resonance 2019 annual meeting, March 26 – 27th, Oxford UK. BMJ Publishing Group Ltd and British Cardiovascular Society, 2019. http://dx.doi.org/10.1136/heartjnl-2019-bscmr.21.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!